Bath Additives for the Treatment of Childhood Eczema

Conditions

Childhood eczema Skin and Connective Tissue Diseases Atopic dermatitis, unspecified

Stuart B, Rumsby K, Santer M, Ridd MJ, Francis NA, Chorozoglou M, Spreadbury C, Steele M, Nollett C, Liddiard L, Prude M, Hooper J, Thomas-Jones E, Roberts A, Thomas KS, Williams HC, Little P.

2018-10-241 citations

10.1186/s13063-018-2962-3

Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT

Miriam Santer, Kate Rumsby, Matthew J Ridd, Nick Francis, Beth Stuart et al. (17 authors)

Health Technology Assessment2018-10-0117 citations

10.3310/hta22570

Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness

Miriam Santer, Matthew J Ridd, Nick Francis, Beth Stuart, Kate Rumsby et al. (17 authors)

BMJ2018-05-0376 citations

10.1136/bmj.k1332

Bath additives for the treatment of childhood eczema (BATHE): protocol for multicentre parallel group randomised trial

Miriam Santer, Kate Rumsby, Matthew J Ridd, Nick Francis, Beth Stuart et al. (11 authors)

BMJ Open2015-10-0111 citations

10.1136/bmjopen-2015-009575

Interventions

Children will be randomised online to either regular bath emollients prescribed by the GP in addition to standard eczema care, or to standard eczema care without bath emollients. The

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged >1 and <12 years with atopic eczema

Exclusion criteria

Exclusion criteria: 1. Children with inactive or very mild eczema (5 or less on Nottingham Eczema Severity Scale) 2. Children who usually have a bath less than once per week

Design outcomes

Primary

Measure	Time frame
Weekly eczema severity measured by POEM (Patient-Oriented Eczema Measure) questionnaires weekly for 16 weeks.	—

Secondary

Measure	Time frame
1. Eczema severity over 1 year by administering POEM every 4 weeks from 16 weeks to 12 months. 2. Number of eczema exacerbations resulting in a primary healthcare consultation over 1 year. This will be assessed by a review of participants' primary care records at 1 year, and exacerbations will be defined as consultations where there is mention of eczema and topical steroid has been advised or prescribed. 3. Disease-specific QoL at baseline, 16 weeks and 1 year, measured by DFI (Dermatitis Family Impact), IDQoL (Infants Dermatitis Quality of Life index) and CDLQI (Childrens Dermatology Life Quality Index). 4. Generic QoL as measured by the Child Health Utility 9D (CHU 9D), a paediatric health related quality of life measure for use in economic evaluations, and the Health Utility Index II (HUI2), a utility measure that has been widely used in paediatric research (the UK valuation tariff will be used). 5. Type (strength) and quantity of topical steroid/calcineurin inhibitors prescribed, measured by GP record review at 12 months.	—

Measure

Time frame

1. Eczema severity over 1 year by administering POEM every 4 weeks from 16 weeks to 12 months. 2. Number of eczema exacerbations resulting in a primary healthcare consultation over 1 year. This will be assessed by a review of participants' primary care records at 1 year, and exacerbations will be defined as consultations where there is mention of eczema and topical steroid has been advised or prescribed. 3. Disease-specific QoL at baseline, 16 weeks and 1 year, measured by DFI (Dermatitis Family Impact), IDQoL (Infants Dermatitis Quality of Life index) and CDLQI (Childrens Dermatology Life Quality Index). 4. Generic QoL as measured by the Child Health Utility 9D (CHU 9D), a paediatric health related quality of life measure for use in economic evaluations, and the Health Utility Index II (HUI2), a utility measure that has been widely used in paediatric research (the UK valuation tariff will be used). 5. Type (strength) and quantity of topical steroid/calcineurin inhibitors prescribed, measured by GP record review at 12 months.

—

Countries

United Kingdom

Outcome results

None listed